We are a patient-driven nonprofit dedicated to researching better therapies and a cure for angiosarcoma.
What is Angiosarcoma?
Clinical Trials
Events & Fundraisers
Research
Join the Angiosarcoma Project!
The Angiosarcoma Project in the News
Samantha Sullivan, September 30, 2018
The American Association for Cancer Research (AACR) issued the following press release focused on the Angiosarcoma Project, whose work is guided by Angiosarcoma Awareness, Inc.’s Vice President Dr. Corrie Painter.   A Patient-partnered Genomics Study Identifies Immunotherapy as Potential Treatment for a Rare Cancer 9/30/2018 ​NEW YORK — Angiosarcoma Project, a patient-partnered genomics study, identified […]
New clinical trial is now recruiting in Boston
Samantha Sullivan, February 13, 2018
A new Phase II clinical trial targeting angiosarcoma is now recruiting patients at Boston’s Massachusetts General Hospital and the Dana-Farber Cancer Institute. For details on this and other available trials, check out the recently updated clinical trials page of our website, which is located under our Resources section.  
Presenting the We Will Prevail 5K!
Samantha Sullivan, January 30, 2018
After taking a year off for a strategic re-brand, we are excited to unveil the return of our community’s beloved 5K event, revamped for its 7th year, in its new location in Herter Park in Boston, MA! Registration is NOW OPEN for the 2018 We Will Prevail 5K- Run, Walk, & Kids Race Benefiting Angiosarcoma […]
Unprecedented angiosarocma research opportunities
Samantha Sullivan, October 13, 2017
Because angiosarcoma is an exceedingly rare cancer, it has never been the focus of large scale scientific endeavors. However, patients are now able to participate in two research projects aimed at understanding this disease in order to make discoveries which may lead to better therapeutic options. Please visit both projects below for more information:   […]
Recently Added

Phase II
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Phase II
ADI- PEG 20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma
Phase II
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
All Clinical Trials
http://cancerres.aacrjournals.org/content/69/18/7175.long
Highlight

Current Research Project

Dr. Antonescu has drafted a budget based on a large scale genomic analysis of angiosarcoma tumors. Her current work has revealed that certain genes are upregulated in angiosarcomas even though there are no genetic mutations associated with the DNA that encodes those genes. The genes of interest are described in the manuscript linked below, many of which are involved in what would be considered “normal” angiogenesis. The fact that she has found them to be differentially regulated in angiosarcoma tumors has led to the hypothesis that there are epigenetic regulators of these genes that have yet to be identified through the genomic profiling applied to these studies thus far.

“Angiosarcoma Awareness combines patient advocacy with research funding.  The results of their efforts have led to numerous patients receiving care at sarcoma centers of excellence, and have translated into rapid progress in understanding this disease on a molecular level with respect to disease research.  Angiosarcoma Awareness provides a resounding voice for patients with angiosarcoma. We truly value our relationship with them and feel fortunate to have such a wonderful ally in our battle against this terrible disease. ”
Dr. William D. Tap, MD Chief
Sarcoma Medical Oncology Service
Memorial Sloan-Kettering Cancer Center
Close